Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial

Eleftheriou D., Connon R., Tulloh R., Martin N., Kucera F., Christov G., Kahn R., Mossberg M., Nordenhäll C., Bailhache M., Palmu S., Webb C., McCrossan B., Herberg J., Moraes YC., McCormack R., Stone J., Hunter R., Walker AS., Brogan P., Merida Morillas M., Pursell M., Papadopoulou C., AlObaidi M., Moraitis E., Walsh J., McLellan K., Ilina M., Jansen M., Iro M., Dewals W., Laan M., Van Onzenoort L., Langer D., Coles W., Paulus S., Williams E., Núñez-Cuadros E., Antón J., Hertting O., De Somer L., Berg S., Panzer J., Meerschaut I., Jõgi P., Huet F., Jeziorski E., von Both U., Jakob A., Krickau T., Rosina S., Simonini G., Taddio A., Fernandez Cooke E., Miller O., Sefi E., Levin M., Swallow V., Wan M., Standing J., Pang K., Wyncoll J.

DOI

10.1016/j.eclinm.2026.104044

Type

Journal article

Publisher

Elsevier BV

Publication Date

2026-07-01T00:00:00+00:00

Volume

97

Pages

104044 - 104044

Total pages

0

Permalink More information Close